This website uses cookies. By using the site you are agreeing to our Privacy Policy.


HOME >> Investor Relations >> Top Message >> Message Archive (April 1, 2016)

PRINT

To Our Investors

A new fiscal year has begun. Here is the latest news about Japan Tissue Engineering (J-TEC).

Management Policy for FY 2016

In the FY 2016, we are going to focus on securing revenues from our new as well existing business, and demonstrate to establish a money-making business model in regenerative medicine industry. Due to the latest revision of the medical payment system, the functional classification of the autologous cultured epidermis JACE and autologous cultured cartilage JACC is more detailed and the reimbursement prices are revised as of April 2016, which is going to help us expand our business of regenerative medicine products. We will expand the application of JACE to giant pigmented nevus at an early point (an application for this partial change has been submitted). Regarding JACC, we will conduct various sales promotional activities to have the product established as a new option for the treatment of knee joints.

We are also planning to bring in revenue from our new business of CRO service specializing in regenerative medicine and contract manufacturing. Behind this plan is a fact that a national policy effort has been made to establish the laws and regulations for regenerative medicine, which has led the academia and corporations to more actively engaging in research and product development. To turn promising technologies into actual products, a broad range of knowledge about pharmaceutical affairs is needed, and this is where we can contribute to. We are, of course, considering the possibility of turning promising technologies into our own products to be approved under the Pharmaceuticals and Medical Devices Law.

J-TEC will accumulate even more successful results and prove that the regenerative medicine industry can thrive. In this process, we may have to venture into something that is completely new to us, but we will bravely tackle any changes.

Successful Meeting of the Japanese Society for Regenerative Medicine

The Annual Congress of the Japanese Society for Regenerative Medicine was held in Osaka from March 17 to 19, 2016. The meeting was deemed a “big success”. Those three days were filled with enthusiastic discussions about latest scientific trends, efforts by the government and regulatory authorities, achievements by the industry, and the future of the industry development. Although this society has a short history of only 15 years, its membership has increased sharply in the last several years. And it is a unique organization where members from the industry as well as the academia are actively involved. With the laws and regulations for regenerative medicine in place, Japan is gaining domestic and international recognition as the country most supportive of advancing regenerative medicine. And at the meeting, I actually felt that the collaborations between academic researchers and corporations are gaining speed.

The achievements and efforts by J-TEC were of course mentioned frequently during the meeting. We have been marketing JACE for 7 years and JACC for 3 years and conducted post-marketing surveillances for all patients. With this track record, we have been regarded as the benchmark for the regenerative medicine industry. Dr. Green, who passed away in October, 2015, once advised us, “Science is valuable only if patients benefit from it in healthcare. Work hard, and make appropriate profits as a corporation.”

The development of the regenerative medicine industry, which is a goal for J-TEC, is progressing steadily. Please look forward to our continued success in FY2016.

Successful luncheon seminar (co-hosted by NIDEK and J-TEC)

Successful luncheon seminar (co-hosted by NIDEK and J-TEC)

April 1, 2016
Yosuke Ozawa
President & CEO
Japan Tissue Engineering Co., Ltd.